帕克利塔塞尔诱导的外围神经病变的遗传决定因素:对当前文献的综述
Swathi Krishna Sivadas1, Aiswarya Das1, Nandana Vijayakumar1
1AmritaCenter for Nanosciences and Molecular medicine, Amrita Vishwa Vidyapeetham, Kochi, Kerala, India.
Drug metabolism reviews
|March 31, 2025
概括
遗传因素影响了对帕克利塔塞尔诱导的周围神经病变 (PIPN) 的易感性. 了解这些遗传变异是开发个性化治疗和改善这种化疗副作用患者治疗结果的关键.
科学领域:
- 在瘤学瘤学.
- 药物基因组学 药物基因组学
- 神经科学是一个神经科学.
背景情况:
- 帕克利塔塞尔是一种重要的化疗药物,但其使用受到帕克利塔塞尔诱导的周围神经病变 (PIPN) 的限制.
- 遗传因素对PIPN易受性的个体差异有很大影响.
- PIPN是一种剂量依赖和使人虚弱的副作用,影响患者的生活质量.
研究的目的:
- 审查帕克利塔塞尔诱导的外围神经病变的遗传基础.
- 确定与PIPN风险相关的关键基因和多态.
- 突出基因标记在个性化癌症治疗中的潜力.
主要方法:
- 关于与PIPN相关的遗传多态的综合文献综述.
- 对参与帕克利塔塞尔代谢,运输,神经炎症和神经元信号传递的基因的分析.
- 专注于CYP基因,ABCB1,SLCO1B1,TNF-α,IL-6,IL-1β,MAPT,TUBB2和SCN9A中的变异.
主要成果:
- 药物代谢基因中的多态性 (例如,CYP2C8,CYP3A4,CYP2C9) 影响着帕克利塔塞尔的处理.
- 药物运输基因 (例如,ABCB1,SLCO1B1) 的变异会影响药物分布和神经毒性.
- 与神经炎症,神经完整性和神经信号传递相关的基因与PIPN易感性有关.
结论:
- 遗传变异在帕克利塔塞尔诱导的外围神经病变的发展中起着至关重要的作用.
- 识别基因标记可以帮助预测PIPN风险和定制化疗方案.
- 整合药物基因组学的个性化医疗方法有望缓解PIPN并优化癌症治疗结果.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
144
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
144
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K


